Ann: Notice of Extraordinary General Meeting/Proxy Form, page-62

First 62 Last

Share
Profile

Follow
lakota6

5,869 Posts.

409

27/03/19

12:34

Post #: 37899473
Share

Originally posted by mg97788 ↑

I tend to agree galilee

My main concern with this stock was cash levels and leverage, the capital raise was 100% necessary and looks to be an appropriate level of cash to fund and grow the company over the next 2 - 3 years - whilst also releasing a substantial amount of debt. Company for mine continues to de-risk.

The company is spending around US$4mio a quarter.... likely to pick up in the next few months. Revenue growth last quarter was 100% - so if the company can achieve that run rate next 2 quarters it will be generating USD5.5mio a quarter. This effectively should be achieved with the Hygea contract - even assuming no further sales contracts coming on. If you add in another Hygea size contract - the company will be getting close to US$40mio revenue per annum (US10mio per quarter). However, cash burn has been heavy, will likely pick up in the next two-three quarters as well as the company ramps up production and marketing - so hard to estimate, and hence the need to capital raise

If you use IRYTHM as a comp - they did US130mio revenue last year (as Low Key mentioned) - market cap of US2bio. So US40mio vs US130mio is about 30% of revenue - 30% of 2bio market cap is 615mio US or AU850mio.

This is just the way im viewing it, and despite the dilution, im happy the leverage is coming out of the company and there is sufficient cash to fund the next 2-3 years of growth.

Im looking for another HYGEA size announcement, increasing revenue growth quarter on quarter in the next 4C and the CFDA approval to hopefully turn the Silverlake MOU to a contract as well.

These are the key requirements for a re-rate of the stock, but as a risk reward trade i like my odds.

DYOR

Expand

Well , that is an impressive first post.

GMV Price at posting: 29.0¢ Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

ASX Market Close: ASX closes above 8,400pts on green Wednesday | Nov 27, 2024

There are more pages in this discussion • 28 more messages in this thread...

First 62 Last

Add GMV (ASX) to my watchlist

Ann: Notice of Extraordinary General Meeting/Proxy Form, page-62

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

ASX Market Close: ASX closes above 8,400pts on green Wednesday | Nov 27, 2024